Tumor penetrating nanomedicine targeting both an oncomiR and an oncogene in pancreatic cancer

Tumor penetrating nanomedicine targeting both an oncomiR and an oncogene in pancreatic cancer

Developing new targeted therapy for pancreatic cancer is one of the major current challenges in cancer research. KRAS mutations and miRNA dysregulation (e.g. miR-21-5p oncomiR) play key roles in Pancreatic Ductal Adenocarcinoma (PDAC), leading to rapid progression of the disease. As the KRAS mutatio...

Full description

Bibliographic Details
Main Authors: Gilles, Maud-Emmanuelle (Author), Hao, Liangliang (Author), Brown, Kaelyn (Author), Lim, Jihoon (Author), Bhatia, Sangeeta N (Author), Slack, Frank J. (Author)
Other Authors: Massachusetts Institute of Technology. Institute for Medical Engineering & Science (Contributor), Koch Institute for Integrative Cancer Research at MIT (Contributor)
Format: Article
Language:English
Published: Impact Journals, LLC, 2020-12-04T21:04:53Z.
Subjects:
Article
Online Access:Get fulltext

Internet

Get fulltext

Similar Items